Julie Tibbets is a partner in Goodwin’s Technology and Life Sciences groups and a member of its FDA practice.

Ms. Tibbets focuses her practice on FDA-regulated product development, marketing and corporate communications as well as the intersection of each of those with corporate strategy and securities disclosure obligations. Her product areas of focus include biologics, drugs, medical devices, in vitro diagnostics, lab-developed tests, as well as digital health tools and apps. Ms. Tibbets advises clients on product development strategy, interactions with the FDA, clinical trial conduct and documentation, adverse event reporting, commercial strategy, product labeling and advertising and FDA inspections. She also leads the regulatory due diligence reviews of FDA-regulated M&A or investment targets, potential collaborators and licensees, and guides the regulatory disclosures of FDA-regulated entities in their initial public offerings. Ms. Tibbets also works closely with the Food + Healthy Living practice team at Goodwin on the intersection of food, supplement and cosmetic regulation with FDA’s drug and device authorities.

Prior to joining Goodwin in 2018, Ms. Tibbets was a partner at Alston & Bird LLP.





  • Represents clinical-stage companies developing COVID-19 focused treatment and vaccines and counsels OTC drug developers on allowable product claims and formulations.
  • Advises early- to late-stage developers in the drug, device, digital health and diagnostic areas on product development pathway strategies, regulatory submissions, meetings with the FDA, data disclosures, expedited program designations, patient engagement, disease awareness programs and corporate communications.
  • Counsels numerous public biopharmaceutical companies on the resolution of clinical holds, including those issued following unexpected patient deaths.
  • Counsels the medical affairs and promotional review committees of biologic, drug, medical device, diagnostic and laboratory companies on managing regulatory risks and ensuring compliant materials and activities across a broad portfolio of products and uses.
  • Drafted a research site agreement and advised on a patient informed consent for the first right to try program in ALS and counsels numerous biopharmaceutical companies on expanded access program policies, agreements, INDs, and related clinical documentation.
  • Conducts internal investigations on regulatory compliance matters, including investigations relating to good clinical practices, product promotion and drug sampling.
  • Counsels on the resolution of Form FDA-483 observations and warning letters.
  • Negotiates the regulatory terms of clinical trial agreements, pharmacovigilance agreements, study site letters of indemnification, clinical collaboration and development agreements, and supply and quality agreements.
  • Advises manufacturers, healthcare providers and distributors on DEA and state controlled substance registration and reporting requirements for the distribution of controlled substances.
  • Provides BridgeBio Pharma and its subsidiaries with regulatory counseling in connection with data releases, clinical operations, medical and corporate communications and regulatory disclosures.
  • Represented AMAG Pharmaceuticals in the sale of its rights to Intrarosa® to Millicent Pharma for up to $125 million.
  • Represented Morgan Stanley & Co. LLC on regulatory matters in conjunction with its underwriting of a $276 million follow-on public offering of Immunomedics, Inc. shares.
  • Represented Akero Therapeutics on regulatory matters in conjunction with its $216.4 million upsized public offering of common stock and full exercise of underwriters’ option to purchase additional shares.
  • Represented Pliant Therapeutics on regulatory matters in conjunction with its $165.6 million IPO and full exercise of option to purchase additional shares.
  • Represented SpringWorks Therapeutics on regulatory matters in conjunction with its $186.3 million IPO.
  • Represented Fresenius Medical Care in regulatory due diligence for its $150 million equity investment in Humacyte, Inc. and exclusive distribution rights for Humacyte’s investigational human acellular vessel, a regenerative medicine product, to dialysis patients worldwide.
  • Represented Nautic Partners on its acquisition of Mikart, Inc., a contract development and manufacturing organization.


Ms. Tibbets represents The Fed Is Best Foundation in its national pursuit of regulatory, legislative, and policy changes to set minimum newborn nutritional requirements and to increase parent and health care provider education regarding newborn nutrition and safe feeding practices.

In 2020, Ms. Tibbets began representing VoteRiders, a nonpartisan, nonprofit organization founded in 2012 with a mission to ensure that all citizens are able to exercise their right to vote.


Ms. Tibbets is a member of the Food and Drug Law Institute, the Regulatory Affairs Professionals Society, and the Drug Information Association.


Ms. Tibbets was selected as an “Up and Coming” lawyer in Washington, D.C. for Pharmaceuticals / Medical Products Regulatory by Chambers USA 2019 and was formally ranked by Chambers USA in 2020 and 2021. Since 2013, she has appeared on the Washington, D.C., Super Lawyers list of “Rising Stars” in the FDA area and has been selected by her peers for inclusion in The Best Lawyers in America every year since 2016 for FDA law. In 2018, LMG named Ms. Tibbets a “Regulatory Star.”

In The News









J.D., 2004
University of North Carolina, Chapel Hill

(Member, Law Review)

B.A., 2001
Purdue University

(Highest Honors, Phi Beta Kappa)



District of Columbia
North Carolina
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique